Cochrane Abstracts
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB: Cochrane systematic review
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB: Cochrane systematic review is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rifamycins (rifampicin, Rifabutin and Rifapentine) Compared to Isoniazid for Preventing Tuberculosis in HIV-negative People at Risk of Active TB: Cochrane Systematic Review." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/436910/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review. Accessed 12 August 2022.
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB: Cochrane systematic review. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/436910/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review. Accessed August 12, 2022.
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB: Cochrane systematic review. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/436910/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review
Rifamycins (rifampicin, Rifabutin and Rifapentine) Compared to Isoniazid for Preventing Tuberculosis in HIV-negative People at Risk of Active TB: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. [cited 2022 August 12]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/436910/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB: Cochrane systematic review
ID - 436910
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/436910/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -
